Session Three: Project ECHO: Evolving Role of Bispecific Antibodies as Cancer Therapy (Diffuse Large B-Cell Lymphoma)

You must have an ACCC account in order to register for Session Two: Project ECHO - Evolving Role of Bispecific Antibodies as Cancer Therapy (Multiple Myeloma).

If You DO NOT Have An ACCC Account:

• To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.
  • ACCC members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page, where you can view and update your information.
  • OSS at ACCC Members: Please use your state society login credentials.
  • Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page, where you can view and update your information. Click “Change” to add your Areas of Concentration, then save your information.
• Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link.
• The green box in the upper right corner of this page will indicate “You are registered!” for this course. Congratulations!

If You Have An ACCC Account:

• Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button.
• You will be automatically redirected back to this webinar page, and the green box in the upper right corner will say that “You are registered!” for this course. Congratulations!

PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar.

Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this Session Two: Project ECHO - Evolving Role of Bispecific Antibodies as Cancer Therapy (Multiple Myeloma). For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org.

Release date: July 3, 2024

Expiration date: July 3, 2025

Bispecific antibodies (BsAbs), an emerging class of novel immunotherapy agents, have great therapeutic potential; however, they also present barriers to care including unique and serious treatment-related toxicities that can preclude their widespread use in the community practice setting. To provide optimal care to patients being treated with BsAbs, clinicians must understand the unique pharmacology and potential clinical and logistical challenges of these agents. Successful administration of BsAbs requires competence and effective collaboration among multidisciplinary providers on the cancer care team.  

Beginning in 2020, the Association of Community Cancer Centers (ACCC) initiated research and education focused on the utilization of BsAbs in the community oncology setting. Findings from an ACCC survey illuminated several barriers to using BsAbs in the community setting. Among these, 59% of survey respondents indicated that they have experienced barriers when caring for patients treated with BsAbs. 

Target Audience: 

The target audience for the initiative includes oncologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with cancer immunotherapies. 

Learning Objectives: 

At the end of this educational activity, participants should be able to: 

• Address barriers to the awareness, preparedness, adoption and use of BsAbs for the treatment of cancer. 

• Improve coordination and communication between community hospitals and academic centers to optimize outcomes for patients beings treated with BsAbs. 

• Review strategies for providing equitable care for underserved patients receiving cancer immunotherapies. 

Accreditation/Designation of Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians' Education Resource®, LLC and the Association of Cancer Care Centers (ACCC). Physicians' Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians. 

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours. 

Pharmacy Times  Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-9999-24-117-H01-P. The activity is available for CE credit through July 3, 2025. 

Acknowledgement of Commercial Support:  

This activity is supported by an educational grant from Genentech. 

Disclosures and Conflict of Interest (COI) Mitigation 

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Faculty, Staff, and Planners’ Disclosures 

The following individuals have no relevant financial relationships with ineligible companies to disclose: Molly Kisiel, MSN, FNP-BC, Mary Stanley, LMSW, PMP, and the staff of Physicians’ Education Resource®, LLC. 

Firas El Chaer, MD - Consultant: SPD Oncology, Amgen, CTI Biopharma, AbbVie,  MorphoSys, ACCC, Other: Travel grant, Dava Oncology

Kirollos Hanna, PharmD, BCPS, BCOP, FACC – Consultant: Seagen, Beigene, BMS; Speakers’ Bureau: Seagen, Beigene, Exelixis, BMS

Amelia Hodson, AG-ACNP - Consultant: Geron

Murali Janakiram, MD, MS – Speaker: Janssen

Joanna Rhodes, MD - Grant/Research Support: Abbvie, Beigene, Janssen, Loxo Oncology, Consultant: Abbvie, Beigene, AstraZeneca, Genentech, Janssen, Genmab, SeaGen, Loxo Oncology